| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
|
Blood
|
2005
|
1.79
|
|
2
|
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
|
Cancer Res
|
2006
|
1.72
|
|
3
|
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
|
Mol Cancer Ther
|
2007
|
1.36
|
|
4
|
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
|
Cancer Res
|
2005
|
1.25
|
|
5
|
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
|
Blood
|
2005
|
1.23
|
|
6
|
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
|
Blood
|
2007
|
1.21
|
|
7
|
Transcriptome analysis of acetate metabolism in Corynebacterium glutamicum using a newly developed metabolic array.
|
Biosci Biotechnol Biochem
|
2002
|
1.03
|
|
8
|
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
|
Oncogene
|
2005
|
0.97
|
|
9
|
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
|
Br J Haematol
|
2008
|
0.96
|
|
10
|
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
|
Blood
|
2005
|
0.95
|
|
11
|
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
|
Blood
|
2005
|
0.95
|
|
12
|
Establishment of a novel monoclonal antibody against LGR5.
|
Biochem Biophys Res Commun
|
2010
|
0.83
|